Quest Diagnostics is scheduled to announce its fiscal second quarter 2026 results before the market opens on Thursday, July 23. Analysts expect the company to report an adjusted earnings per share of $2.81, up 7.3% from $2.62 in the same quarter last year. The company has surpassed Wall Street's bottom-line estimates in the past four quarterly reports. For the full fiscal year 2026, analysts forecast adjusted EPS of $10.72, an 8.8% increase from $9.85 in fiscal 2025. Quest Diagnostics shares have risen 18.2% over the past 52 weeks, outperforming the State Street Health Care Select Sector SPDR ETF's 16.3% gain but lagging the S&P 500 Index's 20.7% return.
Quest Diagnostics Incorporatedanalysts expect 7.3% EPS growth and company has beaten estimates in past four quarters
Advanced Micro Devices Inc